Predicting outcomes in radiation oncology--multifactorial decision support systems - PubMed (original) (raw)
Review
doi: 10.1038/nrclinonc.2012.196. Epub 2012 Nov 20.
Ruud G P M van Stiphout, Maud H W Starmans, Emmanuel Rios-Velazquez, Georgi Nalbantov, Hugo J W L Aerts, Erik Roelofs, Wouter van Elmpt, Paul C Boutros, Pierluigi Granone, Vincenzo Valentini, Adrian C Begg, Dirk De Ruysscher, Andre Dekker
Affiliations
- PMID: 23165123
- PMCID: PMC4555846
- DOI: 10.1038/nrclinonc.2012.196
Review
Predicting outcomes in radiation oncology--multifactorial decision support systems
Philippe Lambin et al. Nat Rev Clin Oncol. 2013 Jan.
Abstract
With the emergence of individualized medicine and the increasing amount and complexity of available medical data, a growing need exists for the development of clinical decision-support systems based on prediction models of treatment outcome. In radiation oncology, these models combine both predictive and prognostic data factors from clinical, imaging, molecular and other sources to achieve the highest accuracy to predict tumour response and follow-up event rates. In this Review, we provide an overview of the factors that are correlated with outcome-including survival, recurrence patterns and toxicity-in radiation oncology and discuss the methodology behind the development of prediction models, which is a multistage process. Even after initial development and clinical introduction, a truly useful predictive model will be continuously re-evaluated on different patient datasets from different regions to ensure its population-specific strength. In the future, validated decision-support systems will be fully integrated in the clinic, with data and knowledge being shared in a standardized, instant and global manner.
Conflict of interest statement
Competing interests
The authors declare no competing interests.
Figures
Figure 1
Schematic overview of methodological processes in clinical decision-support system development, describing model development, assessment of clinical usefulness and what ideally to publish. The coloured, parallel lines represent heterogeneous data, which have been split early for independent validation (but without internal cross-validation).
Figure 2
The importance of considering measured dose for outcome prediction for a patient with prostate cancer. a | Original planning CT scan that includes contours of the prostate (red), bladder (yellow), exterior wall of the rectum (blue) and seminal vesicles (green). b | Contoured CT scan after 16 fractions of radiotherapy. c | Reconstructed 3D dose after 16 fractions of radiotherapy. d | Calculated dose differences (expressed as a 3D Gamma Index) after 16 fractions of radiotherapy. e | Dose–volume histograms at fractions 1, 6, 11, 16, 21 and 26 (dashed lines) as well as pretreatment histograms (solid lines). Clear deviations are visible from the planned dose–volume histogram for the rectum and bladder.
Figure 3
Axial FDG–PET and CT images of two different patients with NSCLC. Tumour imaging biomarkers describing, for example, textural heterogeneity, FDG uptake and tumour size can be assessed noninvasively before, during and after radiotherapy and associated with treatment outcome. Abbreviations: FDG, 18F-fluorodeoxyglucose; NSCLC, non-small-cell lung cancer.
Figure 4
A published nomogram for local control in patients with cancer of the larynx treated with radiotherapy. Clinical and treatment variables are associated with local control status at follow-up durations of 2 and 5 years. The predictors are age of the patient (in years), haemoglobin level (in mmol/l), clinical tumour stage (T-stage), clinical nodal stage (N-stage), patient’s sex and equivalent dose (in Gy). A probability for local control can be calculated by drawing a vertical line from each predictor value to the score scale at the top—’points’. After manually summing up the scores, the ‘total points’ correspond to the probability of local control, which are estimated by drawing a vertical line from this value to the bottom scales to estimate local control.
Figure 5
Knowledge-driven health-care principles using a clinical decision-support system in conjunction with standard evidence and regulations to choose the optimal treatment. In learning from follow-up data, knowledge is fed back to improve the clinical decision-support system and adapt regulations.
Figure 6
A simplified schematic representation of systems biology applied to radiotherapy. a | On the basis of in-vitro, in-vivo and patient data, modules representing the three biological categories (gene expression, immunohistochemical data and mutation data) important for radiotherapy response can be created. b | For an individual patient, appropriate molecular data will be accumulated. c | Combining the individual patient data with the modules will provide knowledge on specific module alterations (such as a deletion [X], upregulation [red] or downregulation [blue]), which can be translated to information on relative radioresistance and the molecular ‘weak’ spots of the tumour. This information will subsequently indicate whether dose escalation is necessary and which targeted drug is most effective for the patient. Part b used with permission from the National Academy of Sciences © Duboisa, L. J. Proc. Natl Acad. Sci. USA 108, 14620–14625 (2011).
Similar articles
- Decision support systems for personalized and participative radiation oncology.
Lambin P, Zindler J, Vanneste BG, De Voorde LV, Eekers D, Compter I, Panth KM, Peerlings J, Larue RT, Deist TM, Jochems A, Lustberg T, van Soest J, de Jong EE, Even AJ, Reymen B, Rekers N, van Gisbergen M, Roelofs E, Carvalho S, Leijenaar RT, Zegers CM, Jacobs M, van Timmeren J, Brouwers P, Lal JA, Dubois L, Yaromina A, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Ramaekers B, Dekker A, Boersma LJ, Hoebers F, Smits KM, Berlanga AJ, Walsh S. Lambin P, et al. Adv Drug Deliv Rev. 2017 Jan 15;109:131-153. doi: 10.1016/j.addr.2016.01.006. Epub 2016 Jan 14. Adv Drug Deliv Rev. 2017. PMID: 26774327 Review. - Decision Support Systems in Oncology.
Walsh S, de Jong EEC, van Timmeren JE, Ibrahim A, Compter I, Peerlings J, Sanduleanu S, Refaee T, Keek S, Larue RTHM, van Wijk Y, Even AJG, Jochems A, Barakat MS, Leijenaar RTH, Lambin P. Walsh S, et al. JCO Clin Cancer Inform. 2019 Feb;3:1-9. doi: 10.1200/CCI.18.00001. JCO Clin Cancer Inform. 2019. PMID: 30730766 Free PMC article. Review. - Radiomics for clinical decision support in radiation oncology.
Russo L, Charles-Davies D, Bottazzi S, Sala E, Boldrini L. Russo L, et al. Clin Oncol (R Coll Radiol). 2024 Aug;36(8):e269-e281. doi: 10.1016/j.clon.2024.03.003. Epub 2024 Mar 15. Clin Oncol (R Coll Radiol). 2024. PMID: 38548581 Review. - Using Big Data Analytics to Advance Precision Radiation Oncology.
McNutt TR, Benedict SH, Low DA, Moore K, Shpitser I, Jiang W, Lakshminarayanan P, Cheng Z, Han P, Hui X, Nakatsugawa M, Lee J, Moore JA, Robertson SP, Shah V, Taylor R, Quon H, Wong J, DeWeese T. McNutt TR, et al. Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):285-291. doi: 10.1016/j.ijrobp.2018.02.028. Epub 2018 Mar 2. Int J Radiat Oncol Biol Phys. 2018. PMID: 29726357 - Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy.
Enderling H, Alfonso JCL, Moros E, Caudell JJ, Harrison LB. Enderling H, et al. Trends Cancer. 2019 Aug;5(8):467-474. doi: 10.1016/j.trecan.2019.06.006. Epub 2019 Jul 10. Trends Cancer. 2019. PMID: 31421904 Review.
Cited by
- Identification of Calculous Pyonephrosis by CT-Based Radiomics and Deep Learning.
Yuan G, Cai L, Qu W, Zhou Z, Liang P, Chen J, Xu C, Zhang J, Wang S, Chu Q, Li Z. Yuan G, et al. Bioengineering (Basel). 2024 Jun 28;11(7):662. doi: 10.3390/bioengineering11070662. Bioengineering (Basel). 2024. PMID: 39061744 Free PMC article. - Predictive machine learning models for ascending aortic dilatation in patients with bicuspid and tricuspid aortic valves undergoing cardiothoracic surgery: a prospective, single-centre and observational study.
Gaye B, Vignac M, Gådin JR, Ladouceur M, Caidahl K, Olsson C, Franco-Cereceda A, Eriksson P, Björck HM. Gaye B, et al. BMJ Open. 2024 Mar 20;14(3):e067977. doi: 10.1136/bmjopen-2022-067977. BMJ Open. 2024. PMID: 38508639 Free PMC article. - Artificial general intelligence for radiation oncology.
Liu C, Liu Z, Holmes J, Zhang L, Zhang L, Ding Y, Shu P, Wu Z, Dai H, Li Y, Shen D, Liu N, Li Q, Li X, Zhu D, Liu T, Liu W. Liu C, et al. Meta Radiol. 2023 Nov;1(3):100045. doi: 10.1016/j.metrad.2023.100045. Epub 2023 Nov 24. Meta Radiol. 2023. PMID: 38344271 Free PMC article. - CT radiomics for predicting the prognosis of patients with stage II rectal cancer during the three-year period after surgery, chemotherapy and radiotherapy.
Zhang H, Deng Y, Xiaojie MA, Zou Q, Liu H, Tang N, Luo Y, Xiang X. Zhang H, et al. Heliyon. 2023 Dec 27;10(1):e23923. doi: 10.1016/j.heliyon.2023.e23923. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38223741 Free PMC article. - Standardized Radiomics Analysis of Clinical Myocardial Perfusion Stress SPECT Images to Identify Coronary Artery Calcification.
Ashrafinia S, Dalaie P, Schindler TH, Pomper MG, Rahmim A. Ashrafinia S, et al. Cureus. 2023 Aug 11;15(8):e43343. doi: 10.7759/cureus.43343. eCollection 2023 Aug. Cureus. 2023. PMID: 37700937 Free PMC article.
References
- Vogelzang NJ, et al. Clinical cancer advances 2011: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012;30:88–109. - PubMed
- Fraass BA, Moran JM. Quality, technology and outcomes: evolution and evaluation of new treatments and/or new technology. Semin Radiat Oncol. 2012;22:3–10. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources